Search results for " type 2"

showing 10 items of 761 documents

Predictors of early discontinuation of dapagliflozin versus other glucose-lowering medications: a retrospective multicenter real-world study

2020

Background and aims: In routine clinical practice, early discontinuation of newly initiated glucose-lowering medications (GLM) is relatively common. We herein evaluated if the clinical characteristics associated with early discontinuation of dapagliflozin were different from those associated with early discontinuation of other GLM. Methods: The DARWIN-T2D was a multicenter retrospective study conducted at diabetes specialist outpatient clinics in Italy. We included 2484 patients who were initiated on dapagliflozin in 2015–2016 and 14,801 patients who were initiated on other GLM (DPP-4 inhibitors, GLP-1 receptor agonists, or gliclazide) in the same period. After excluding patients who had no…

Blood GlucoseMalemedicine.medical_specialtyEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismType 2 diabetes03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyGlucosidesDiabetes mellitusInternal medicineAdherence; Observational; Pharmacotherapy; Real-world; Type 2 diabetes; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Retrospective Studies; Withholding TreatmentDiabetes MellitusmedicineHumansHypoglycemic AgentsOutpatient clinicBenzhydryl CompoundsDapagliflozinObservationalAgedRetrospective StudiesDipeptidyl-Peptidase IV InhibitorsAdherence; Observational; Pharmacotherapy; Real-world; Type 2 diabetesbusiness.industryType 2 diabetesRetrospective cohort studyMiddle Agedmedicine.diseasePharmacotherapyMetforminDiscontinuationDiabetes Mellitus Type 2Real-worldWithholding TreatmentchemistryTolerabilityAdherence030220 oncology & carcinogenesisFemalebusinessType 2medicine.drugJournal of Endocrinological Investigation
researchProduct

Leisure time physical activity in individuals with screen-detected type 2 diabetes compared to those with known type 2 diabetes.

2008

Abstract Aims To investigate whether leisure time physical activity (LTPA) characteristics differ between individuals with previously undiagnosed (screen-detected) and those with previously diagnosed (known) type 2 diabetes. Methods A population-based random sample of 1364 (participation rate 61%) men and 1461 (65%) women aged 45–74 years participated in a cross-sectional health examination including an oral glucose tolerance test and physical activity assessment by a self-administered questionnaire. Results Women with screen-detected type 2 diabetes ( n =110) were physically less active than those with known type 2 diabetes ( n =68) with differences in the duration of physical activity ses…

Blood GlucoseMalemedicine.medical_specialtyEndocrinology Diabetes and MetabolismLeisure timePopulationPhysical activityType 2 diabetesBody Mass IndexHealth examinationEndocrinologyLeisure ActivitiesInternal medicineDiabetes mellitusInternal MedicineMedicineBody SizeHumansMass ScreeningeducationExerciseAgedRelated factorseducation.field_of_studyScreen detectedbusiness.industryPatient SelectionGeneral MedicineGlucose Tolerance TestMiddle Agedmedicine.diseaseDiabetes Mellitus Type 2Physical therapyEducational StatusFemalebusinessDiabetes research and clinical practice
researchProduct

Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial.

2021

Digital

Blood GlucoseMalemedicine.medical_specialtyEndocrinology Diabetes and MetabolismRecombinant Fusion ProteinsGlucagon-Like Peptides030209 endocrinology & metabolismType 2 diabetesPlacebolaw.invention03 medical and health sciences0302 clinical medicineEndocrinologyRandomized controlled trialDouble-Blind MethodErectile DysfunctionlawInternal medicineDiabetes mellitusInternal MedicinemedicineHumansHypoglycemic Agents030212 general & internal medicineRisk factorAgedbusiness.industryIncidence (epidemiology)Middle Agedmedicine.diseasePrognosisImmunoglobulin Fc FragmentsErectile dysfunctionDiabetes Mellitus Type 2Cardiovascular DiseasesDulaglutideFemalebusinessBiomarkersmedicine.drugFollow-Up StudiesThe lancet. Diabetesendocrinology
researchProduct

Tubular markers are associated with decline in kidney function in proteinuric type 2 diabetic patients.

2011

Our aim was to investigate u-NGAL, u-KIM1 and p-FGF23 and prediction of decline in kidney function in type 2 diabetic patients with proteinuria.We performed a follow-up study, follow-up median (range) 3.5 (1-5) years. At baseline u-NGAL, u-KIM1 and p-FGF23 (ELISA) was measured and patients were followed yearly with estimated(e)-GFR (MDRD) and u-albumin.We included 177 patients (44 women), mean age (SD) 59 (9) years. eGFR 90 (24) ml/min/1.73 m(2) at baseline, u-albumin: median (interquartile range) 104 (39-238) mg/24 h. Patients with levels of u-KIM1 in the highest quartile had a greater decline in eGFR than patients with the lowest quartile 6.0 (5.4) versus 3.2 (5.5) ml/min/1.73 m(2) per ye…

Blood GlucoseMalemedicine.medical_specialtyEndocrinology Diabetes and MetabolismUrologyRenal functionEnzyme-Linked Immunosorbent AssayType 2 diabetesKidneyEnd stage renal diseaseDiabetic nephropathyEndocrinologyInterquartile rangeDiabetes mellitusInternal medicineInternal MedicinemedicineHumansDiabetic NephropathiesProteinuriabusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseFibroblast Growth Factor-23ProteinuriaEndocrinologyKidney TubulesQuartileDiabetes Mellitus Type 2Disease ProgressionFemalemedicine.symptombusinessBiomarkersAcute-Phase ProteinsFollow-Up StudiesGlomerular Filtration RateDiabetes research and clinical practice
researchProduct

Effects on α- and β-cell function of sequentially adding empagliflozin and linagliptin to therapy in people with type 2 diabetes previously receiving…

2017

Aims The aim of the study was to investigate the effect of sequential treatment escalation with empagliflozin and linagliptin on laboratory markers of alpha- and beta cell function in patients with type 2 diabetes mellitus (T2DM) insufficiently controlled on metformin monotherapy. Methods Forty-four patients with T2DM received 25 mg empagliflozin for a duration of one month in an open-label fashion (treatment period (TP 1). Thereafter, patients were randomised to a double-blind add-on therapy with linagliptin 5 mg or placebo (TP 2) for one additional month. Alpha- and beta cell function were assessed with a standardised liquid meal test (LMT) and an intravenous (iv.) glucose challenge. Effi…

Blood GlucoseMalemedicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatment030209 endocrinology & metabolismLinagliptinType 2 diabetes030204 cardiovascular system & hematologyLinagliptinGlucagon03 medical and health sciences0302 clinical medicineEndocrinologyDouble-Blind MethodGlucosidesInternal medicineInsulin-Secreting CellsInternal MedicinemedicineEmpagliflozinHumansHypoglycemic AgentsInsulinBenzhydryl CompoundsProinsulinAgedbusiness.industryInsulinMiddle Agedmedicine.diseaseGlucagonPostprandial PeriodMetforminEndocrinologyPostprandialTreatment OutcomeDiabetes Mellitus Type 2Glucagon-Secreting CellsGlucose Clamp TechniqueFemalebusinessmedicine.drugProinsulinDiabetes, obesitymetabolism
researchProduct

Effects of heparin treatment on hemostatic abnormalities in obese non-insulin-dependent diabetic patients.

1997

This study was conducted to identify the mechanisms responsible for coagulative and fibrinolytic alterations and to study the effects of a short-term treatment with low-dose heparin on hemostatic abnormalities in obese non-insulin-dependent diabetes mellitus (NIDDM) patients. Four groups of age- and sex-matched patients were studied: (1) lean nondiabetic subjects (n = 30) with a body mass index (BMI) less than 25 kg/m2 (lean control subjects), (2) obese nondiabetic subjects (n = 30) with a BMI greater than 30 kg/m2 (obese control subjects), (3) lean NIDDM patients (n = 30), and (4) obese NIDDM patients (n = 30). All subjects were tested on the following parameters: fibrinogen, factor VII, p…

Blood GlucoseMalemedicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentFibrinogenTissue plasminogen activatorBody Mass Indexchemistry.chemical_compoundEndocrinologyInternal medicineFibrinolysismedicineHumansInsulinObesityBlood CoagulationHemostasisFactor VIIbusiness.industryHeparinFibrinolysisnutritional and metabolic diseasesAnticoagulantsHeparinMiddle AgedLipidsBlood Coagulation FactorsEndocrinologychemistryDiabetes Mellitus Type 2HemostasisCase-Control StudiesFemalebusinessPlasminogen activatorBody mass indexmedicine.drugMetabolism: clinical and experimental
researchProduct

Implication of corticotropic hormone axis in eating behaviour pattern in obese and type 2 diabetic participants.

2015

In Algeria, eating behaviour has been increasingly deviated from its traditional Mediterranean diet to modern fast food style. The present study examines the interactions between eating behaviour pattern (EBP), corticotropic hormone axis and the metabolic syndrome. Our Algerian population cohort comprised of 410 participants (130 obese, 170 type 2 diabetics and 110 healthy participants). The EBP was evaluated by the Three-Factor Eating Questionnaire test. The anthropometric and metabolic parameters (glucose, TAG, HDL, LDL and cholesterol) and the concentrations of hormones (insulin, adrenocorticotropin hormone (ACTH), cortisol and growth hormone) were determined by biometrics, spectrophotom…

Blood GlucoseMalemedicine.medical_specialtyHydrocortisonemedicine.medical_treatmentRadioimmunoassayMedicine (miscellaneous)Adipose tissueType 2 diabetesDiet MediterraneanCohort StudiesInsulin resistanceAdrenocorticotropic HormoneInternal medicineDiabetes mellitusSurveys and QuestionnairesmedicineHumansInsulinObesityGlycated HemoglobinMetabolic SyndromeNutrition and DieteticsAnthropometrybusiness.industryInsulinCholesterol HDLCholesterol LDLFeeding Behaviormedicine.diseaseObesityDietEndocrinologyDiabetes Mellitus Type 2AlgeriaGrowth HormoneMultivariate AnalysisFemaleMetabolic syndromebusinessHormoneThe British journal of nutrition
researchProduct

Benefits of a home-based physical exercise program in elderly subjects with type 2 diabetes mellitus

2011

Abstract Objective To analyze the effects of a home-based physical exercise program on quality of life, metabolic control, and anthropometric and biochemical parameters in people over 60 years of age with type 2 diabetes mellitus. Methods Eighty-four Spanish patients aged over 60 years were finally randomized to participate in a home-based, combined physical exercise program (aerobic and anaerobic exercises) or to receive conventional treatment for diabetes. At 6 months, effects on quality of life (EuroQoL questionnaire), HbA1c, fasting glucose, hypoglycemic events, weight, BMI, waist circumference, blood pressure, and biochemical parameters were assessed. Results Mean age of study particip…

Blood GlucoseMalemedicine.medical_specialtyPatient DropoutsPhysical exerciseType 2 diabetesElectrocardiographyQuality of lifeWeight lossDiabetes mellitusDiet DiabeticWeight LossHumansHypoglycemic AgentsMedicineProspective StudiesAgedGlycemicGlycated Hemoglobinbusiness.industryType 2 Diabetes MellitusMiddle Agedmedicine.diseaseCombined Modality TherapyHome Care ServicesLipidsHypoglycemiaExercise TherapyHouse CallsDiabetes Mellitus Type 2Quality of LifePhysical therapyFemaleWaist Circumferencemedicine.symptombusinessAnaerobic exerciseProgram EvaluationEndocrinología y Nutrición (English Edition)
researchProduct

Ventricular remodelling in rabbits with sustained high-fat diet.

2013

Aim Excess weight gain and obesity are one of the most serious health problems in the western societies. These conditions enhance risk of cardiac disease and have been linked with increased prevalence for cardiac arrhythmias and sudden death. Our goal was to study the ventricular remodelling occurring in rabbits fed with high-fat diet (HFD) and its potential arrhythmogenic mechanisms. Methods We used 15 NZW rabbits that were randomly assigned to a control (n = 7) or HFD group (n = 8) for 18 weeks. In vivo studies included blood glucose, electrocardiographic, and echocardiographic measurements. Optical mapping was performed in Langendorff-perfused isolated hearts. Results Body weight (3.69 ±…

Blood GlucoseMalemedicine.medical_specialtyPhysiologyAction PotentialsBiologyDiet High-FatWeight GainQT intervalSudden deathMuscle hypertrophyElectrocardiographyInternal medicineDiabetes mellitusmedicineRepolarizationAnimalsVentricular RemodelingArrhythmias CardiacHeartmedicine.diseaseObesitymedicine.anatomical_structureEndocrinologyDiabetes Mellitus Type 2VentricleVentricular fibrillationCardiologyHypertrophy Left VentricularRabbitsActa physiologica (Oxford, England)
researchProduct

Effect of vildagliptin compared to glimepiride on postprandial proinsulin processing in the β cell of patients with type 2 diabetes mellitus

2012

This study compared the effect of Glimepiride versus Vildagliptin on β-cell function and the release of intact proinsulin (PI) in patients with type 2 diabetes mellitus. Patients on metformin monotherapy were randomized to add on treatment with Vildagliptin or Glimepiride. A standardized test meal was given at baseline, after 12 and 24 weeks of treatment. Insulin, PI and blood glucose values were measured in the fasting state and postprandial for 300 min. Fasting PI levels significantly decreased in the Vildagliptin group. The area under the curve for the postprandial release of PI decreased during Vildagliptin and increased during Glimepiride treatment. The proinsulin to insulin ratio decl…

Blood GlucoseMalemedicine.medical_specialtyPyrrolidinesendocrine system diseasesEndocrinology Diabetes and Metabolismmedicine.medical_treatmentAdamantaneEndocrinologyDiabetes mellitusInternal medicineNitrilesInternal MedicinemedicineHumansHypoglycemic AgentsVildagliptinProinsulinVildagliptinDipeptidyl-Peptidase IV Inhibitorsbusiness.industryInsulinnutritional and metabolic diseasesType 2 Diabetes MellitusPostprandial Periodmedicine.diseaseMetforminMetforminGlimepirideSulfonylurea CompoundsTreatment OutcomePostprandialEndocrinologyDiabetes Mellitus Type 2Area Under CurveDrug Therapy CombinationFemalebusinessProinsulinmedicine.drugDiabetes, Obesity and Metabolism
researchProduct